Description: <p><b>Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol)</b> = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.<br>
<b>Primary mechanisms (conceptual rank):</b><br>
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).<br>
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).<br>
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).<br>
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).<br>
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).<br>
<b>PK / bioavailability:</b> well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.<br>
<b>In-vitro vs systemic exposure:</b> many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).<br>
<b>Clinical evidence status:</b> strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.</p>
<b>Hydroxytyrosol </b> is mostly only available from olive oil and leaves, but is available as a common supplement.<br>
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).<br>
<pre>
Hydroxytyrosol is potent against CSC phenotypes.
Mechanisms:
-Blocks EMT, reducing transition into CSC-like states
-Inhibits Notch signaling
-Reduces CD44+ / CD24– CSC markers
-Inhibits hypoxia-driven stemness (HIF-1α suppression)
Hydroxytyrosol is especially active in:
-Breast CSCs
-Melanoma CSC-like cells
-Gastric CSC models
</pre>
<p><b>Hydroxytyrosol (HT)</b> — a naturally occurring small phenolic alcohol and catechol-type polyphenol, chemically 2-(3,4-dihydroxyphenyl)ethanol (3,4-dihydroxyphenylethanol; DOPET), found in olives, extra-virgin olive oil and olive-derived extracts and also generated from oleuropein metabolism. It is classified as a dietary polyphenol / nutraceutical bioactive rather than an approved anticancer drug. HT is strongly redox-active, but its biological behavior is context-dependent: antioxidant and cytoprotective effects predominate at nutritional exposures and in normal tissues, whereas substantially higher concentrations can produce pro-oxidant stress and cancer-cell death. Oral HT is available in olive-derived supplements and as purified hydroxytyrosol.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of cancer-cell apoptosis and cell-cycle arrest through modulation of BAX/BCL-2, caspases, p21/p27 and cyclin/CDK signaling.</li>
<li>Suppression of oncogenic PI3K/AKT, STAT3 and NF-κB signaling in multiple cancer models.</li>
<li>Suppression of tumor stemness, EMT and metastatic signaling through Wnt/β-catenin, TGF-β, EMT transcription factors and associated CSC phenotypes.</li>
<li>Redox modulation with preferential ROS elevation at higher anticancer concentrations; HT can shift from antioxidant to pro-oxidant behavior depending on concentration and cellular redox state.</li>
<li>EGFR downregulation through receptor ubiquitination and enhanced lysosomal/proteasomal degradation in colorectal cancer models.</li>
<li>Ferroptosis induction in some colorectal cancer models through ↓ NRF2/NQO1, ↓ SLC7A11/GPX4/GSH, ↑ iron, ↑ ROS and ↑ lipid peroxidation; this is highly context- and concentration-dependent.</li>
<li>Suppression of migration, invasion and angiogenic signaling, including MMPs, HIF-1α and VEGF in selected models.</li>
<li>NRF2-mediated antioxidant and cytoprotective signaling in non-malignant systems; this mechanism is secondary and can oppose ferroptotic or ROS-dependent anticancer strategies.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> HT is absorbed after oral administration but undergoes rapid and extensive intestinal and hepatic metabolism, particularly sulfation, glucuronidation, methylation and oxidation. Circulating free hydroxytyrosol is therefore low and transient, while conjugated metabolites predominate. The food or pharmaceutical matrix materially affects exposure; lipid-based matrices such as extra-virgin olive oil can increase apparent bioavailability. Human studies using approximately 5–45 mg oral HT demonstrate measurable systemic exposure and generally good short-term tolerability.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> A major translational limitation is the concentration gap. Many anticancer experiments use approximately 25–200 µM HT, and some older cancer models require several hundred µM for substantial growth inhibition. These concentrations are far above measured free-HT plasma concentrations after ordinary dietary or supplement dosing. Consequently, direct cytotoxic, ferroptotic and CSC-suppressive mechanisms demonstrated at high in-vitro concentrations should not be assumed to occur systemically after standard oral supplementation.</p>
<p><b>Clinical evidence status:</b> Small human studies and randomized trials support systemic antioxidant, anti-inflammatory and cardiometabolic effects of oral HT, and a small 12-month study has investigated 25 mg/day HT in women at increased breast-cancer risk. There is currently no established therapeutic RCT evidence demonstrating treatment of an existing human cancer by hydroxytyrosol, and it is not an approved cancer therapy. Oncology evidence remains predominantly cell-culture and animal/xenograft evidence; clinical use should therefore be classified as investigational / dietary adjunct rather than anticancer treatment.</p>
<h3>Hydroxytyrosol Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Apoptosis and cell-cycle control</td>
<td>↑ apoptosis; ↑ BAX:BCL-2; ↑ caspases; ↑ p21/p27; ↓ cyclin D1/E; ↓ CDK2/4</td>
<td>↔ / substantially less cytotoxicity (model-dependent)</td>
<td>R–G</td>
<td>Growth arrest and programmed cell death</td>
<td>One of the most consistently reproduced anticancer phenotypes; cancer-selective effects have been reported in prostate and colon models, although usually at concentrations above typical systemic nutritional exposure.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K AKT STAT3 signaling</td>
<td>↓ PI3K; ↓ p-AKT; ↓ STAT3 (model-dependent)</td>
<td>↔ / context-dependent</td>
<td>R–G</td>
<td>Reduced survival and proliferation signaling</td>
<td>Observed in prostate, hematological, melanoma and other cancer models. Direction can differ under ROS-dependent stress, so AKT modulation is not universal.</td>
</tr>
<tr>
<td>3</td>
<td>Wnt β-catenin TGF-β and cancer stemness</td>
<td>↓ Wnt/β-catenin; ↓ TGF-β; ↓ EMT; ↓ CSC phenotype</td>
<td>↔ / context-dependent</td>
<td>G</td>
<td>Reduced stemness, invasion and metastatic phenotype</td>
<td>Particularly relevant to triple-negative breast-cancer models. Evidence remains preclinical and generally requires direct cellular exposure substantially above circulating free HT after dietary intake.</td>
</tr>
<tr>
<td>4</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓ NF-κB; ↓ nuclear p65 (model-dependent)</td>
<td>↓ inflammatory NF-κB signaling</td>
<td>R–G</td>
<td>Anti-inflammatory and anti-survival signaling</td>
<td>Can contribute to inhibition of proliferation and inflammatory tumor signaling while also providing anti-inflammatory effects in non-malignant cells.</td>
</tr>
<tr>
<td>5</td>
<td>EGFR receptor turnover</td>
<td>↓ EGFR</td>
<td>Not well characterized</td>
<td>R–G</td>
<td>Reduced proliferative receptor signaling</td>
<td>HT can promote Cbl-associated EGFR ubiquitination followed by lysosomal and proteasomal degradation in colorectal cancer models.</td>
</tr>
<tr>
<td>6</td>
<td>Pro-oxidant ROS stress</td>
<td>↑ ROS (high concentration only)</td>
<td>↓ ROS at nutritional or protective exposure</td>
<td>P–R</td>
<td>Oxidative-stress-mediated tumor-cell killing</td>
<td>Important dual behavior: HT is normally considered an antioxidant, but high exposure can increase ROS in colon cancer, melanoma and other malignant cells and contribute to apoptosis or ferroptosis.</td>
</tr>
<tr>
<td>7</td>
<td>Ferroptosis and System Xc GPX4</td>
<td>↑ ferroptosis; ↓ SLC7A11; ↓ GPX4; ↓ GSH; ↑ iron; ↑ lipid peroxidation (high concentration only)</td>
<td>↓ lipid oxidation under antioxidant conditions</td>
<td>R–G</td>
<td>Iron-dependent oxidative cell death</td>
<td>Demonstrated in HCT116 and SW480 colorectal cancer cells. This conflicts with treating HT as an intrinsically anti-ferroptotic antioxidant; direction is strongly dependent on tumor type and exposure.</td>
</tr>
<tr>
<td>8</td>
<td>NRF2 NQO1 redox defense</td>
<td>↓ in ferroptosis-sensitive colorectal models; ↑ or ↔ in other contexts</td>
<td>↑ (context-dependent)</td>
<td>R–G</td>
<td>Context-dependent control of endogenous antioxidant defenses</td>
<td>NRF2 should not be assigned one universal direction for HT. Activation is frequently reported in protective non-cancer models, whereas HT suppressed NRF2/NQO1 during colorectal-cancer ferroptosis. Human HT administration has not consistently demonstrated NRF2-dependent Phase II enzyme induction.</td>
</tr>
<tr>
<td>9</td>
<td>Mitochondrial dysfunction and membrane potential</td>
<td>↓ mitochondrial membrane potential (high concentration only)</td>
<td>↑ mitochondrial protection (context-dependent)</td>
<td>R</td>
<td>Facilitates stress-induced cancer-cell death</td>
<td>Another example of differential redox biology: high anticancer concentrations can disrupt mitochondrial function, while nutritional exposure can protect mitochondria in non-malignant tissues.</td>
</tr>
<tr>
<td>10</td>
<td>Migration invasion and angiogenic signaling</td>
<td>↓ MMP2/MMP9; ↓ HIF-1α; ↓ VEGF; ↓ migration/invasion (model-dependent)</td>
<td>↔ / context-dependent</td>
<td>G</td>
<td>Reduced metastatic and angiogenic phenotype</td>
<td>Supported by several preclinical systems but substantially less clinically established than apoptosis and growth-signaling effects.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Systemic exposure limits direct anticancer translation</td>
<td>Rapid Phase II metabolism and low circulating free HT mean that many 25–200 µM or higher experimental exposures are unlikely to be reproduced by ordinary oral supplementation. No established therapeutic cancer efficacy in humans.</td>
</tr>
</tbody>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<h3>Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>EMT (Epithelial–Mesenchymal Transition)</td>
<td>↓ (model-/dose-dependent)</td>
<td>↔</td>
<td>R→G</td>
<td>Reduces EMT-associated transcription (e.g., Snail, Twist)</td>
<td>Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.</td>
</tr>
<tr>
<td>2</td>
<td>CSC markers (CD44<sup>+</sup>/CD24<sup>–</sup>)</td>
<td>↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Reduces stemness-associated phenotype</td>
<td>Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.</td>
</tr>
<tr>
<td>3</td>
<td>Notch signaling</td>
<td>↓ (model-dependent)</td>
<td>↔</td>
<td>R→G</td>
<td>Stemness pathway inhibition</td>
<td>Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.</td>
</tr>
<tr>
<td>4</td>
<td>HIF-1α / hypoxia-driven stemness</td>
<td>↓ (preclinical)</td>
<td>↔</td>
<td>R→G</td>
<td>Suppresses hypoxia adaptation</td>
<td>Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.</td>
</tr>
<tr>
<td>5</td>
<td>Tumor-type specificity</td>
<td>Breast, Melanoma, Gastric (preclinical)</td>
<td>—</td>
<td>—</td>
<td>CSC-like cell sensitivity</td>
<td>Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.</td>
</tr>
</table>
<p><b>TSF Legend:</b> P: 0–30 min | R: 30 min–3 hr | G: >3 hr</p>
<br><br>
<p><b>Alzheimer's disease relevance:</b> Hydroxytyrosol has credible preclinical neuroprotective activity, particularly through reduction of oxidative stress and neuroinflammation, preservation of mitochondrial function and modulation of proteostasis/autophagy. Effects on amyloid pathology are inconsistent across animal models: some studies report reduced Aβ burden whereas others report cognitive and mitochondrial improvement without altered APP processing or Aβ accumulation. Human evidence specific to Alzheimer’s disease remains insufficient; cognitive studies of HT-rich olive preparations should not be interpreted as demonstrating treatment of AD.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Reduction of neuronal oxidative stress and lipid/protein oxidation.</li>
<li>Suppression of NF-κB-associated neuroinflammatory signaling.</li>
<li>Preservation of mitochondrial function and endogenous antioxidant defenses.</li>
<li>Enhancement of autophagy/proteostasis in selected AD models.</li>
<li>Reduction of Aβ toxicity and, in some models, Aβ plaque burden; effects on amyloid processing are inconsistent.</li>
<li>NRF2/SKN-1 antioxidant-response activation in experimental systems.</li>
</ol>
<p><b>Clinical evidence status:</b> Preclinical animal and cellular evidence with limited indirect human cognitive evidence. There is no convincing clinical evidence that isolated hydroxytyrosol prevents, slows or treats established Alzheimer’s disease.</p>
<h3>Hydroxytyrosol Alzheimer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Oxidative stress and lipid oxidation</td>
<td>↓ ROS; ↓ oxidative damage</td>
<td>P–R</td>
<td>Neuronal protection</td>
<td>Among the most consistent HT effects across neurodegenerative experimental systems.</td>
</tr>
<tr>
<td>2</td>
<td>Neuroinflammation and NF-κB</td>
<td>↓ NF-κB; ↓ inflammatory signaling</td>
<td>R–G</td>
<td>Reduced neuronal and glial inflammatory stress</td>
<td>HT attenuates Aβ-associated NF-κB activation in cellular systems and reduces inflammatory markers in animal models.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial integrity</td>
<td>↑</td>
<td>R–G</td>
<td>Improved bioenergetic resilience</td>
<td>Animal evidence supports reduced mitochondrial oxidative injury and improved mitochondrial function.</td>
</tr>
<tr>
<td>4</td>
<td>Autophagy and proteostasis</td>
<td>↑ (model-dependent)</td>
<td>G</td>
<td>Clearance of damaged or aggregation-prone proteins</td>
<td>Autophagy induction has accompanied cognitive improvement and reduced neuropathology in some transgenic AD models.</td>
</tr>
<tr>
<td>5</td>
<td>Amyloid β toxicity and deposition</td>
<td>↓ (model-dependent)</td>
<td>G</td>
<td>Reduced amyloid-associated neurotoxicity</td>
<td>Some models show reduced Aβ42 or plaque burden, whereas APP/PS1 experiments have reported neurological benefit without reduced Aβ accumulation. Therefore this should not be presented as a universal HT mechanism.</td>
</tr>
<tr>
<td>6</td>
<td>NRF2 antioxidant response</td>
<td>↑ (model-dependent)</td>
<td>R–G</td>
<td>Enhanced cellular stress resistance</td>
<td>Supported strongly by experimental models, but direct NRF2/Phase II activation after oral HT has not been convincingly demonstrated in humans.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>—</td>
<td>—</td>
<td>Insufficient human AD evidence</td>
<td>Human cognitive studies involve olive-derived preparations or non-AD populations; isolated HT has not demonstrated disease-modifying efficacy in Alzheimer’s disease.</td>
</tr>
</tbody>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br>